Alzheimer Disease

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2018 English Publisher:Elsevier BVJournal:Clinics in Geriatric Medicine, volume 34, pages 591-601 (issn: 0749-0690,

Copyright policy )

Authors: John E, Morley; Susan A, Farr; Andrew D, Nguyen;

doi: 10.1016/j.cger.2018.06.006

pmid: 30336989

Alzheimer Disease

- Summary
- Subjects
- Metrics

Abstract

Alzheimer disease is due to increased amyloid-β coupled with low progranulin. Several brain imaging techniques are helpful in the diagnosis. Drugs available for treating Alzheimer disease have limited clinical utility. Cognitive stimulation therapy is an effective therapy for persons with moderate Alzheimer disease.

Related Organizations

University of Mary
United States
VA Office of Research and Development
United States
Rehabilitation Research and Development Service
United States

Keywords

Amyloid beta-Peptides, Progranulins, Cognitive Behavioral Therapy, Alzheimer Disease, Brain, Disease Management, Humans, Genetic Predisposition to Disease, Neuropsychological Tests, Aged

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	52
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%